临床误诊误治2025，Vol.38Issue(10)：38-44,7.DOI:10.3969/j.issn.1002-3429.2025.10.007
肝动脉化疗栓塞术联合替雷利珠单抗治疗原发性肝癌的效果及对促癌、抑癌基因的影响
Efficacy of Transcatheter Arterial Chemoembolization Combined with Tislelizumab in the Treatment of Primary Liver Cancer and Its Impact on Cancer-promoting and Cancer-suppressing Genes
摘要
Abstract
Objective To investigate the efficacy of transcatheter arterial chemoembolization(TACE)combined with Tislelizumab in the treatment of primary liver cancer and its impact on cancer-promoting and cancer-suppressing genes.Methods Seventy-five patients with primary liver cancer admitted from October 2018 to March 2023 were selected,and then assigned to the control group(n=37)and the observation group(n=38)using the random number table method.Both groups were treated with Lenvatinib.On this basis,the control group received TACE,while the observation group received TACE combined with Tislelizumab.The efficacy,adverse reactions,and short-term survival rate,as well as the changes in tumor markers,angiogenesis-related factors,immune function indicators,and the expression of cancer-promoting and cancer-suppressing genes proteins before and after treatment,were compared between the two groups.Results The objective re-sponse rate and disease control rate in the observation group were higher than those in the control group(P＜0.05).After treatment,the levels of serum carcinoembryonic antigen,carbohydrate antigen 19-9,cytokeratin 19,alpha-fetoprotein,acidic fibroblast growth factor,vascular endothelial growth factor,basic fibroblast growth factor,and matrix metalloproteinase-9 in the observation group were lower than those in the control group(P＜0.05).After treatment,the levels of peripheral blood CD3+,CD4+/CD8+,and CD4+in the observation group were higher than those in the control group.The expression lev-els of peripheral blood monocyte cysteine aspartate-specific protease-3 and phosphatidylinositol 3-kinase proteins were higher in the observation group than in the control group,while the expression levels of B lymphocyte tumor-2 and extracellular signal-regulated kinase proteins were lower in the observation group than in the control group(P＜0.05).There were no significant differences in the incidence of adverse reactions and post-treatment survival rates between the two groups(P＞0.05).Conclusion In the treatment of primary liver cancer,TACE combined with Tislelizumab can improve the therapeutic effect,inhibit neovascularization,and promote immune function recovery,showing a certain degree of safety.Its mechanism may be related to regulating the expression of cancer-promoting and cancer-suppressing gene,but it does not significantly improve sur-vival rate.关键词
原发性肝癌/肝动脉化疗栓塞术/替雷利珠单抗/肿瘤标志物/血管生成/癌基因/抑癌基因/生存率Key words
Primary liver cancer/Transcatheter arterial chemoembolization/Tislelizumab/Tumor marker/Angio-genesis/Oncogene/Antioncogene/Survival rate分类
临床医学引用本文复制引用
赵仰光,李傲,张倩,闫绍辉,李建梅..肝动脉化疗栓塞术联合替雷利珠单抗治疗原发性肝癌的效果及对促癌、抑癌基因的影响[J].临床误诊误治,2025,38(10):38-44,7.基金项目
河北省2021年度医学科学研究课题(20210772) （20210772）
